Search results
Results from the WOW.Com Content Network
Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. [4] For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. [5]
Please refer to the entry on isoniazid for details on other neurological side effects of INH. [citation needed] Rashes are most frequently due to PZA, but can occur with any of the TB drugs. Test dosing using the same regimen as detailed below for hepatitis may be necessary to determine which drug is responsible.
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin.
It is a fixed dose combination of ethambutol, isoniazid, pyrazinamide, and rifampicin. [1] It is used either alone or with other antituberculosis medication. [1] It is taken by mouth. [1] Side effects are those of the underlying medications. [1] Pyridoxine may be used to decrease the risk of numbness. [2]
It contains ethambutol, isoniazid, and rifampicin. [1] ... Side effects are those of the underlying medications. [1] Use may not be suitable in children. [1]
Isoniazid/rifampicin, also known as isoniazid/rifampin, is a medication used to treat tuberculosis. [1] It is a fixed dose combination of isoniazid and rifampicin (rifampin). [1] It is used together with other antituberculosis medication. [1] It is taken by mouth. [1] It is on the World Health Organization's List of Essential Medicines. [2]
The original method used to test for MDR-TB and XDR-TB was the Drug Susceptibility Testing (DST). DST is capable of determining how well four primary antitubercular drugs inhibit the growth of Mycobacterium tuberculosis. The four primary antitubercular drugs are Isoniazid, Rifampin, Ethambutol and Pyrazinamide. [7]
"Current standard therapy is isoniazid (INH) which reduce the risk of active TB by as much as 90 per cent (in patients with positive LTBI test results and fibrotic pulmonary lesions compatible with tuberculosis [31]) if taken daily for 9 months."